WS #15846
Verastem Oncology released initial data from its TARGET-D 101 Phase 1/2 trial, showing robust clinical activity for its pancreatic cancer drug VS-7375, with a 41% confirmed objective response rate. In related healthcare news, Liquidia received an upgrade from BTIG to Buy with a $70 price target, although Needham lowered its target to $58. These developments highlight the ongoing importance of clinical trial results and analyst sentiment in driving healthcare stock performance.
Healthcare Clinical & M&A Activity
Verastem Oncology released initial data from its TARGET-D 101 Phase 1/2 trial, showing robust clinical activity for its pancreatic cancer drug VS-7375, with a 41% confirmed objective response rate. In related healthcare news, Liquidia received an upgrade from BTIG to Buy with a $70 price target, although Needham lowered its target to $58. These developments highlight the ongoing importance of clinical trial results and analyst sentiment in driving healthcare stock performance.